Investigators from University of Strasbourg Report New Data on Cancer Vaccines [Targeted Delivery of alpha-Galactosylceramide to CD8 alpha(+) Dendritic Cells Optimizes Type I NKT Cell-Based Antitumor Responses]
By a News Reporter-Staff News Editor at Vaccine Weekly -- Current study results on Immunization have been published. According to news reporting from Illkirch Graffenstaden, France, by NewsRx journalists, research stated, "Immunotherapy aiming at enhancing innate and acquired host immunity is a promising approach for cancer treatment. The invariant NKT (iNKT) cell ligand a-galactosylceramide (alpha-GalCer) holds great promise in cancer therapy, although several concerns limit its use in clinics, including the uncontrolled response it promotes when delivered in a nonvectorized form."
The news correspondents obtained a quote from the research from the University of Strasbourg, "Therefore, development of delivery systems to in vivo target immune cells might be a valuable option to optimize iNKT cellbased antitumor responses. Using dendritic cell (DC)-depleted mice, DC transfer experiments, and in vivo active cell targeting, we show that presentation of alpha-GalCer by DCs not only triggers optimal primary iNKT cell stimulation, but also maintains secondary iNKT cell activation after challenge. Furthermore, targeted delivery of a-GalCer to CD8 alpha(+) DCs, by means of anti-DEC205 decorated nanoparticles, enhances iNKT cell-based transactivation of NK cells, DCs, and gd T cells. We report that codelivery of a-GalCer and protein Ag to CD8 alpha+ DCs triggers optimal Ag-specific Ab and cytotoxic CD8 alpha(+) T cell responses. Finally, we show that targeting nanoparticles containing a-GalCer and Ag to CD8 alpha(+) DCs promotes potent antitumor responses, both in prophylactic and in therapeutic settings."
According to the news reporters, the research concluded: "Our data may have important implications in tumor immunotherapy and vaccine development."
For more information on this research see: Targeted Delivery of alpha-Galactosylceramide to CD8 alpha(+) Dendritic Cells Optimizes Type I NKT Cell-Based Antitumor Responses. Journal of Immunology, 2014;193(2):961-969. Journal of Immunology can be contacted at: Amer Assoc Immunologists, 9650 Rockville Pike, Bethesda, MD 20814, USA. (The American Association of Immunologists - www.aai.org; Journal of Immunology - www.jimmunol.org)
Our news journalists report that additional information may be obtained by contacting E. Macho-Fernandez, Univ Strasbourg, CNRS, Unite Mixte Rech 7199, F-67401 Illkirch Graffenstaden, France. Additional authors for this research include L.J. Cruz, R. Ghinnagow, J. Fontaine, E. Bialecki, B. Frisch, F. Trottein and C. Faveeuw (see also Immunization).
Keywords for this news article include: Antigen-Presenting Cells, France, Europe, Immunology, Cerebrosides, Immunization, Nanoparticle, Immunotherapy, Nanotechnology, Cancer Vaccines, Dendritic Cells, Immunomodulation, Galactosylceramides, Emerging Technologies, Illkirch Graffenstaden, Mononuclear Phagocyte System
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC